NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…
Search results for: nonmelanoma skin cancer
Cancer & RA Drugs: Are Some Drugs Riskier than Others?
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk
NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…
Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors
WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link. The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included…
Does Methotrexate Increase Skin Cancer Risk?
A recent study connects the use of immunosuppressant and biologic agents to an increased risk of nonmelanoma skin cancer in patients being treated for RA and IBD…
2014 ACR/ARHP Annual Meeting: Autoimmune Connective Tissue Diseases and Cancer
Links between autoimmunity, malignancy prompt rheumatologists to include cancer screening for patients
15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions
Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.
Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…
FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…
Rheumatology Drugs at a Glance, Part 2: Psoriasis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…